Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans

This report is a distillation of two tandem conferences, the first entitled “AAPS, ACCP, ASCPT, FDA Symposium on Clinical Pharmacology: Optimizing the Science of Drug Development,” held in September, 1998 in Arlington, Virginia, USA, and the second entitled “5 EUFEPS Conference on Optimizing Drug Development: Fast Tracking into Human,” held in December, 1998 in Wiesbaden, Germany. The collective aims of these conferences were:

[1]  S L Shafer,et al.  Pharmacokinetics, pharmacodynamics, and rational opioid selection. , 1991, Anesthesiology.

[2]  P. Glass,et al.  Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra‐Short‐Acting Opioid: Remifentanil (GI87084B) , 1993, Anesthesia and analgesia.

[3]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[4]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[5]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[6]  David J. Hermann,et al.  The Pharmacokinetics of the New Short‐acting Opioid Remifentanil (GI87084B) in Healthy Adult Male Volunteers , 1993, Anesthesiology.

[7]  Carl Peck,et al.  An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development , 1997, Clinical pharmacokinetics.

[8]  J. Newhouse,et al.  Econometrics in outcomes research: the use of instrumental variables. , 1998, Annual review of public health.

[9]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[10]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. T. Viswanathan,et al.  Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.

[12]  B. Chabner,et al.  Pharmacologically guided phase I clinical trials based upon preclinical drug development. , 1990, Journal of the National Cancer Institute.